AZN stock icon

AstraZeneca

68.20 USD
+0.67
0.99%
At close Dec 6, 4:00 PM EST
After hours
68.00
-0.20
0.29%
1 day
0.99%
5 days
0.99%
1 month
6.81%
3 months
-17.88%
6 months
-15.63%
Year to date
-0.29%
1 year
7.25%
5 years
43.04%
10 years
86.54%
 

About: A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

Employees: 89,900

0
Funds holding %
of 6,790 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

45% more call options, than puts

Call options by funds: $485M | Put options by funds: $334M

23% more repeat investments, than reductions

Existing positions increased: 489 | Existing positions reduced: 398

7% more first-time investments, than exits

New positions opened: 111 | Existing positions closed: 104

1% more funds holding

Funds holding: 1,196 [Q2] → 1,203 (+7) [Q3]

1.87% less ownership

Funds ownership: 32.98% [Q2] → 31.11% (-1.87%) [Q3]

6% less capital invested

Capital invested by funds: $39.9B [Q2] → $37.6B (-$2.3B) [Q3]

11% less funds holding in top 10

Funds holding in top 10: 18 [Q2] → 16 (-2) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for AZN.

Financial journalist opinion

Based on 100 articles about AZN published over the past 30 days

Neutral
Accesswire
17 hours ago
AZN STOCK ALERT: Levi & Korsinsky Notifies AstraZeneca PLC Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
AZN STOCK ALERT: Levi & Korsinsky Notifies AstraZeneca PLC Investors of an Ongoing Investigation
Neutral
Business Wire
1 day ago
Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--A pooled analysis of the TROPION-Lung05 phase 2 and the TROPION-Lung01 phase 3 trials showed datopotamab deruxtecan (Dato-DXd) demonstrated clinically meaningful tumor response in patients with previously treated advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). These data, along with progression-free and overall survival results from the analysis, were presented during a late-breaking proffered paper session (LBA7) at the 2024.
Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis
Positive
Zacks Investment Research
1 day ago
AstraZeneca's Imfinzi Gets FDA Nod for Expanded Use in SCLC
The FDA approves AZN's Imfinzi for treating patients with limited-stage small-cell lung cancer based on phase III ADRIATIC study data.
AstraZeneca's Imfinzi Gets FDA Nod for Expanded Use in SCLC
Positive
Zacks Investment Research
1 day ago
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Neutral
Accesswire
1 day ago
AstraZeneca PLC (AZN) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
AstraZeneca PLC (AZN) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
Neutral
Business Wire
1 day ago
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. The approval was granted by the Food and Drug Administration (FDA) after securing Priority Review and Breakthrough Therapy Designation. It was based on results from the ADRIATIC Phase III trial which were pr.
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
Positive
Proactive Investors
1 day ago
US regulator approves AstraZeneca's Imfinzi for small cell lung cancer
AstraZeneca PLC's (LSE:AZN) Imfinzi (durvalumab) has received approval from the U.S. Food and Drug Administration (FDA) as the first immunotherapy treatment for limited-stage small cell lung cancer (LS-SCLC).
US regulator approves AstraZeneca's Imfinzi for small cell lung cancer
Positive
Reuters
2 days ago
FDA approves AstraZeneca's Imfinzi for limited-stage small cell lung cancer
The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with limited-stage small cell lung cancer, the health regulator said on Wednesday.
FDA approves AstraZeneca's Imfinzi for limited-stage small cell lung cancer
Neutral
Business Wire
2 days ago
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) investors concerning the Company's possible violations of federal securities laws. On November 5, 2024, news outlets reported that a fraud investigation linked to AstraZeneca had expanded to several Chinese government agencies, implicating dozens of senior executives at the Company. On this news, AstraZeneca's stock price fell $5.1.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
Neutral
Business Wire
2 days ago
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your AstraZeneca investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securitie.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
Charts implemented using Lightweight Charts™